Table 4

Incidence and risk of individual solid cancer subtypes

 sDMARDTNFiETAINFADA
N=3249N=11 767N=4073N=3457N=4327
Lung cancer
 Number40103492529
 Incidence rate per 10 000 patient-years (95% CI)34 (24 to 47)20 (16 to 24)22 (16 to 29)20 (13 to 30)16 (11 to 23)
 Unadjusted HR (95% CI)Referent0.57 (0.40 to 0.82)0.64 (0.42 to 0.98)0.59 (0.36 to 0.97)0.49 (0.29 to 0.76)
 Age and sex adjusted HR (95% CI)Referent0.81 (0.56 to 1.17)0.95 (0.62 to 1.46)0.81 (0.49 to 1.35)0.64 (0.40 to 1.04)
 PD-adjusted HR (95% CI)Referent0.85 (0.52 to 1.39)1.02 (0.58 to 1.76)0.92 (0.50 to 1.71)0.69 (0.39 to 1.23)
Female breast cancer
 Number2273301825
 Incidence rate per 10 000 patient-years (95% CI)34 (20 to 48)18 (14 to 22)17 (11 to 23)19 (10 to 28)17 (10 to 23)
 Unadjusted HR (95% CI)Referent0.72 (0.45 to 1.17)0.70 (0.40 to 1.22)0.76 (0.41 to 1.42)0.74 (0.42 to 1.31)
 Age adjusted HR (95% CI)Referent0.83 (0.51 to 1.35)0.83 (0.47 to 1.45)0.86 (0.46 to 1.61)0.83 (0.47 to 1.48)
 PD-adjusted HR (95% CI)Referent0.58 (0.32 to 1.06)0.56 (0.28 to 1.10)0.59 (0.28 to 1.24)0.59 (0.31 to 1.15)
Colorectal cancer
 Number1943161017
 Incidence rate per 10 000 patient-years (95% CI)16 (9 to 25)8 (6 to 11)7 (4 to 12)8 (4 to 15)9 (5 to 15)
 Unadjusted HR (95% CI)Referent0.52 (0.30 to 0.89)0.46 (0.24 to 0.90)0.50 (0.23 to 1.07)0.59 (0.31 to 1.14)
 Age and sex adjusted HR (95% CI)Referent0.71 (0.41 to 1.23)0.66 (0.33 to 1.29)0.67 (0.31 to 1.44)0.79 (0.41 to 1.52)
 PD-adjusted HR (95% CI)Referent0.51 (0.24 to 1.06)0.45 (0.19 to 1.05)0.47 (0.19 to 1.20)0.57 (0.26 to 1.27)
Gastro-oesophageal cancer
 Number1220857
 Incidence rate per 10 000 patient-years (95% CI)10 (5 to 18)4 (2 to 6)4 (2 to 7)4 (1 to 9)4 (2 to 8)
 Unadjusted HR (95% CI)Referent0.35 (0.17 to 0.73)NRNRNR
 Age and sex adjusted HR (95% CI)Referent0.51 (0.24 to 1.05)NRNRNR
 PD-adjusted HR (95% CI)Referent0.59 (0.23 to 1.52)NRNRNR
  • NR, not reported (indicates fewer than 10 events in each cohort so comparative analyses were not performed).

  • ADA, adalimumab; ETA, etanercept; INF, infliximab; PD, propensity score stratified into deciles; sDMARD, synthetic disease modifying antirheumatic drug; TNFi, tumour necrosis factor inhibitors.